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Abstract The latent precursors of the matrix metallopro- 
teinases (MMPs) are converted by (4-aminophenylmercu- 
ric)acetate to active forms that lose their propeptide as a result 
of autolysis. C.D. and an active site mutant of progelatinase A
(MMP2) were used to demonstrate that, although propeptide 
removal is accompanied by a decrease in the enzyme's /]-sheet 
content, the initial activation is achieved with only minor modifi- 
cations to the conformation. Mixing activated gelatinase A with 
the natural inhibitor, TIMP-1, resulted in conformational 
changes that were absent when a synthetic inhibitor was used. The 
relevance of these results to MMP activation and inhibition is 
discussed. 
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1. Introduction 
The matrix metalloproteinases (MMPs) are a family of zinc- 
dependent proteinases that contribute to the turnover of the 
extracellular matrix [1]. Interest in the mechanisms that regu- 
late their activity has been stimulated by the proposed role of 
MMPs in mediating a variety of clinical disorders [2]. The 
MMPs are secreted from cells as inactive proenzymes whose 
latency is maintained by an approximately 80 amino acid N- 
terminal propeptide. Once activated the MMPs are subject to 
inhibition by one of the three known tissue inhibitors of metal- 
loproteinases (TIMP-1, -2 or -3) [3]. 
The physiological mechanism of proenzyme activation is 
most likely to be the removal of the propeptide by serine pro- 
teinase or active MMP catalysed hydrolysis [4-6]. The same 
end-result can be achieved, however, by treatment of the proen- 
zymes with organomercurials such as 4-(aminophenylmercu- 
ric)acetate (APMA) [7] and the study of this convenient in vitro 
system of MMP activation has led to an increased understand- 
ing of how proenzyme latency is controlled. The organomercu- 
rials bind to a conserved propeptide cysteine and thereby break 
an interaction that would otherwise xist between this residue 
and the active site zinc [8 10]. The interaction plays a key role 
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tant of progelatinase A; McaPLGLDpaAR, (7-methoxycoumarin-4- 
yl)acetyl-Pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diaminopropi- 
onyl]-Ala-Arg-NH z. 
in maintaining proenzyme latency because it prevents the zinc 
from recruiting a water molecule ssential to the catalytic mech- 
anism. Once the active site is liberated there follows a series of 
autolytic cleavages to the proenzyme that serve to remove the 
propeptide. The initial cleavage is an intramolecular event be- 
cause the rate of proenzyme disappearance is not dependent 
upon its own starting concentration [11-12]. This supports the 
concept hat the addition of APMA must in the first instance 
generate an active MMP that still possesses a complete propep- 
tide. It has been proposed that the initial activation requires 
significant alterations to the conformation of the proenzyme 
[10] and this report sets out to directly demonstrate the exist- 
ence and extent of any changes that might occur. Gelatinase A
(EC 3.4.24.24.; MMP2; 72 kDa gelatinase) is used as a repre- 
sentative member of the family and we have overcome the 
difficulty of deciding whether a conformational alteration to 
the proenzyme is the result of activation or the accompanying 
loss of the propeptide by studying the effect of APMA on 
proE375--+A. This is an active site mutant of proge- 
latinase A that possesses only 0.01% of the normal proteolytic 
activity after activation and so displays a correspondingly re- 
duced rate of propeptide removal [13]. We have also used C.D. 
to investigate whether or not any substantial conformational 
alteration accompanies the inhibition of gelatinase A by either 
TIMP-1 or a low molecular mass synthetic inhibitor. 
2. Materials and methods 
2.1. Materials 
Recombinant forms of human progelatinase A, (,J418 631)progelati- 
nase A, proE 375 -->A, and human TIMP-1 were purified and their con- 
centrations determined as previously described [13 15]. A peptide hy- 
droxamate derivative that is a reversible inhibitor of MMPs (CT989) 
was supplied by the Chemistry Department of Celltech Therapeutics 
Ltd. It has a K~ against gelatinase A of 10 pM [16 (Ref no. 31)]. 
2.2. Proenzyme activation 
Progelatinase A and (A418-63 l)progelatinase A were fully activated 
by their incubation with 1 mM APMA for at least 2 h at 23°C. The 
APMA was removed from activated (A418-631)gelatinase A by gel 
filtration using Sephadex G-25. The propeptide-lacking mutant 
(E375----)A) was generated by incubating 20 ~tM proE375----)A 
with 5,uM activated (A418-631)gelatinase A and 1 mM APMA at 37°C 
for 105 min. E 375 ~ A was then isolated using heparin Sepharose CL-6B 
as previously described [13]. All reactions were performed in 25 mM 
Tris/HCl, 30 mM NaC1, 10 mM CaC12, pH 7.5 (buffer A). 
2.3. Enzyme assay 
Gelatinase A activity was assayed by following the increase in fluo- 
rescence that accompanied hydrolysis of the synthetic substrate (7- 
methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)- 
L-2,3diaminopropionyl]-Ala-Arg-NH 2 (McaPLGLDpaAR) as previ- 
usly described [17-18] and with a gelatinase A concentration i the 
assay of 100 pM. 
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2.4. CD. 
C.D. spectra of samples presented in Buffer A were recorded at 23 ° C 
on a JASCO J-600 spectropolarimeter using cells of path lengths 0.02 
or 0.05 cm. Molar ellipticity values were calculated using a value of 114 
for the mean residue weight. Analysis of the C.D. spectra for secondary 
structure content was performed using the CONTIN procedure [19]. 
2.5. SDS-PAGE 
Samples taken for analysis were immediately boiled in standard run- 
ning buffer containing 2% (v/v) 2-mercaptoethanol and 30 mM EDTA 
and run on precast 10 20% polyacrylamide g ls (Daichii, Tokyo). Pro- 
tein was visualised using Coomassie Brilliant Blue R-250. 
3. Results 
3.1. APMA-induced activation of progelatinase A 
The results in Fig. la illustrate how the activation of proge- 
latinase A by APMA is accompanied by a decrease in its molec- 
ular mass. At the start of the incubation progelatinase A dis- 
played < 0.1% of maximum activity and a molecular mass of 72 
kDa. Full activity was achieved after approximately 2 h, at 
which point the proenzyme had been converted to a 66 kDa 
form that, according to previous studies, lacks the 80 amino 
acid N-terminal propeptide [12]. 50% of maximum activity was 
achieved at a time ( -20 min) when approximately half of the 
proenzyme had been processed. No decrease in molecular mass 
occurred if the incubation with APMA was performed in the 
presence of excess quantities of TIMP-1 or the synthetic inhib- 
itor, CT989 (results not shown). An active site mutant ofproge- 
latinase A, which has an alanine residue as a replacement for 
the catalytically essential glutamic acid (proE375--> A), has been 
expressed and purified [13]. The addition of 1 mM APMA was, 
on its own, unable to alter the position of migration of 
proE 375~A, which remained at 72 kDa throughout 
a 2 h incubation (Fig. lb). The 66 kDa form that lacks the 
propeptide (E375---~ A) could be generated, however, by a cleav- 
age catalysed by APMA-activated (A418-631)gelatinase A.
This reaction proceeded at a relatively slow rate that was signif  
icantly enhanced if 1 mM APMA was added at the start of the 
incubation. A 2 h preincubation with APMA did not increase 
the rate any further but complete propeptide removal could be 
achieved within 2 h if the incubation temperature was set to 
37°C (results not shown). The (A418-631)gelatinase A had al- 
ready been activated to its maximum, so it is most likely that 
the APMA exerted its effect by increasing the susceptibility of 
the proE375~A propeptide to intermolecular cleavage. The 
rate of propeptide loss was still approximately 6 times slower 
than that displayed by the wild type proenzyme. This presum- 
ably reflects the fact that the wild type proenzyme is cleaved by 
an intramolecular reaction [12], which tends to raise the effec- 
tive substrate concentration [20]. 
3.2. Analysis" by C.D. of progelatinase A activation 
The results in Fig. 2 show that, prior to APMA addition, tile 
C.D. spectrum of progelatinase A is nearly identical to that of 
proE375---~A. This agrees with previously obtained results, 
which demonstrated that the alteration of this glutamic acid 
residue had little or no effect on the conformation of the proen- 
zyme [13]. A 2 h incubation of the two proenzymes at 23°C 
made no difference to their C.D. spectra (results not shown). 
Analysis of the progelatinase A spectrum over the range 240 
205 nm by the CONTIN  procedure [19] yielded the following 
estimates of secondary structure: 0% co-helix, 61% fl-sheet and 
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Fig. 1. The removal of the propeptide from progelatinase A. (a) Proge- 
latinase A (2 ,uM) was incubated with 1 mM APMA at 23°C and, at 
selected time points, an aliquot was removed and assayed for prote- 
olytic activity as described in section 2. The same aliquots were also 
analysed by SDS-PAGE (inset). Molecular mass marker proteins were 
run in lane M. (b) ProE375--*A (2 pM) was incubated at 23°C with 
either no additions, 1 mM APMA, 2/,tM activated (A418-631)gelati- 
nase A or 1 mM APMA + 2 ~tM activated (A418q531)gelatinase A as 
indicated. At set time points, aliquots from each incubation were re- 
moved and analysed by SDS-PAGE. 
39% remainder. These values should be treated with caution in 
view of the relatively low molar ellipticities and the restricted 
range of wavelengths over which the analysis was carried out. 
The C.D. spectrum of wild type progelatinase A displayed an 
progressive alteration upon addition of APMA that mirrored 
the gain in enzymic activity and the loss of the propeptide (Fig. 
2a). The removal of APMA and propeptide fragments by gel 
filtration had no effect on the final spectrum (results not 
shown). According to the CONTIN  analysis over the range 
240-205 nm, the change in the spectrum corresponds to a de- 
crease in the fl-sheet content (to 52%) and an increase in the 
remainder (to 48%) but, again, these figures must be treated 
with caution. In contrast, the C.D. spectrum of proE375--+A 
was not altered uring the 2 h incubation with APMA (Fig. 2b). 
Thus the transition of proE375--->A from a latent to an 'active' 
state and the increased susceptibility of its propeptide to autol- 
ysis were not accompanied by any significant changes to the 
secondary structure. The alterations observed with the wild 
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Fig. 2. C.D. analysis of progelatinase A activation. APMA (l mM) was 
added to 6 pM solutions of either progelatinase A (a) or proE~75---)A 
(b). In (a) the spectra were recorded before the addition of APMA (solid 
line) and 30 min (dashed line), 60 min (dotted line), 90 min (dash-dot- 
dash line) and 120 min (dash-dot-dot-dash line) after the addition of 
APMA. In (b) the spectra were recorded before the addition of APMA 
(solid line) and 120 min after the addition of APMA (dashed line). The 
C.D. profile of a 3 pM solution of E 375 ---~A is also given (dotted line). 
type proenzyme must simply have been the result of propeptide 
removal. In accordance with this proposal, the C.D. profile of 
E 375 ---> A was similar to the spectra of APMA-treated wild type 
enzyme (Fig. 2b). It is not an exact match but this might be 
because the purification method employed id not remove the 
low levels of contaminating breakdown products that are also 
generated uring the incubation with APMA and (A418 
631)gelatinase A [13]. 
3.3. Analysis by C.D. of gelatinase A inhibition 
Conformational changes that might accompany gelatinase A 
inhibition were also studied by C.D. This was done by subtract- 
ing the C.D. spectrum of TIMP-1 from the spectrum of an 
equimolar mixture of TIMP-1 and gelatinase A and comparing 
the results obtained with those of a control where buffer A 
replaced inhibitor. There was no difference between the spectra 
when inhibitor was added to progelatinase A (Fig. 3a), an 
expected result because the latent proenzyme is unable to inter- 
act with either TIMP-1 [13] or synthetic inhibitors [21]. The 
spectrum of activated wild type gelatinase A and TIMP-1, how- 
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ever, is significantly different to that of the buffer control (Fig. 
3b). This result does not indicate as to whether the implied 
structural change was the result of an alteration to the inhibitor, 
the enzyme or a combination of both. It is not integral to 
the process of gelatinase A inhibition, however, because the 
C.D. spectrum of activated wild type gelatinase A in the pres- 
ence of excess CT989 was no different from that of the buf- 
fer control (results not shown). The spectrum of TIMP-1 
(Fig. 3c) is broadly similar to that described previously 
[221. 
4. Discussion 
The results which show that the activation of progelatinase 
A is accompanied by conformational changes detectable by 
C.D. are similar to those obtained in a study of the APMA- 
induced activation of prostromelysin-1 [101. By using an active 
site mutant, however, we have been able to demonstrate hat 
these changes are not a consequence of the proenzyme convert- 
ing from a latent o an active state but occur instead as a result 
of the concomitant dissolution of the propeptide. It is also 
shown that gelatinase A inhibition can be achieved without 
the conformational lterations that occur upon TIMP-I addi- 
tion. 
The crystal structure of progelatinase A has not yet been 
solved. Even so, the estimates of its secondary structure as 
determined by C.D. (high fl-sheet and negligible a-helix con- 
tent) are only partly in accord with the recently published crys- 
tal structures of porcine fibroblast collagenase [23] and a dele- 
tion mutant of human prostromelysin 1 [24]. The C-terminal 
domain of collagenase is predominantly fl-sheet but both struc- 
tures have regions of a-helix in their catalytic domains that are 
made up of sequences similar to those found in human gelati- 
nase A. Estimates of c~-helix content using the CONTIN proce- 
dure are sensitive to the levels of noise in the region between 
200 and 190 nm so the discrepancy is probably due to our 
inability to obtain good quality C.D. data below 205 nm. Our 
results also suggest that the propeptide of progelatinase A con- 
tains some fl-sheet. This would make it markedly different o 
the propeptide of prostromelysin-1, which has 3 short a-helices 
but no fl-sheet [24]. 
Although APMA destroys the cysteine-zinc interaction of 
the proenzyme, this event is, on its own, insufficient for activa- 
tion [10]. An additional contribution is required and it is possi- 
ble that the organomercurial also disrupts interactions involv- 
ing amino acids situated upstream of the conserved cysteine 
[25]. These alterations do not affect he far U.V.C.D. spectrum 
of the proenzyme but they nevertheless erve to both liberate 
the active site and perturb the propeptide's conformation such 
that it becomes ubject o rapid autolytic leavage. It is only 
after the propeptide has been at least partially removed that the 
hydrolysis of exogenous substrates can be detected. This is not 
because access to the active site is still blocked as TIMP-1 and 
the zinc-chelating inhibitor CT989 were able to prevent 
APMA-induced autolysis. A more likely explanation is that the 
propeptide's enforced proximity to the active site will ensure 
that it is at a considerably higher localised concentration than 
other substrates [20], which will tend to be excluded from hy- 
drolysis. This also explains why the initial cleavage of the wild 
type proenzyme is by an intra- and not an intermolecular u- 
tolytic event. APMA-induced MMP activation is different, 
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Fig. 3. C.D. analysis of gelatinase A inhibition by TIMP-I. Progelati- 
nase A (a) and activated gelatinase A (b) were incubated for 1 h at 4 ° C 
with either an equal concentration (3/IM) of TIMP-I (dashed line) or 
the equivalent volume of buffer A (solid line) before being analysed by 
C.D. The spectra of the TIMP-1 containing samples are corrected for 
the contribution of TIMP-1 alone (shown as (c)). For clarity in (a) the 
corrected spectrum of the TIMP-l-containing sample has been offset 
by + 100 deg.cm2.dmol -l. 
therefore, to that brought about by serine proteinases, where 
propeptide removal is the cause, rather than an effect, of activa- 
tion [4]. It need not be physiologically irrelevant, however, 
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because the existence of biological systems that activate the 
MMPs in a manner analogous to the organomercurials cannot 
be ruled out. 
The precise mechanism by which the TIMPs inhibit the 
MMPs has not yet been elucidated. It is known that they inter- 
act with the active site [26] and studies using deletion mutants 
of the TIMPs and MMPs have shown that secondary interac- 
tions occur between other sites of the enzyme and inhibitor that 
serve to increase the association rate constant [27 28]. The data 
presented in this report support the view that inhibition by the 
TIMPs is a complex, multifactorial process because no struc- 
tural changes detectable by C.D. were observed when CT989 
was used to inhibit gelatinase A. Detailed structural studies of 
the T IMP complex using, for example, X-ray crystallography 
will be required in order to define the interactions and confor- 
mational changes more precisely. 
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